Most Read Articles
one year ago
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Jackey Suen, one year ago
Several biomarker candidates may improve screening and monitoring of treatment response in colorectal cancer (CRC), inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC), say experts of the Department of Medicine and Therapeutics, Chinese University of Hong Kong (CUHK), at the CUHK’s Advances in Medicine 2015 conference.
one year ago
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.
one year ago
In an exclusive interview with MIMS Doctor, renowned gastroenterologists from Subang Jaya Medical Centre, Dr Tan Soon Seng and Dr Ranjeev C K Prabhakeran,
shared their perspectives and experiences on the use of Fuse® (Full Spectrum Endoscopy) in their clinical practice. Both of them have been practicing gastroenterology
for almost 20 years and have completed more than 1,200 procedures using the Fuse® system.

Fuse® has been available in Malaysia since January 2015. Subang Jaya Medical Centre is the first medical centre in Asia and the ONLY one in Malaysia to use the
Fuse® at the present moment. As cited in The Lancet Oncology,1 March 2014, Fuse® Endoscopy System detected 69% more pre-cancerous polyps than standard forwardviewing colonoscopy.

Serum chemerin tied to quality of life in colorectal cancer survivors

8 days ago

Serum chemerin levels have a weak but significant association with quality of life (QoL) of survivors of colorectal cancer (CRC), a new study shows.

The study included 110 survivors (mean age 56.29±9.27 years; 50 percent male) of stage 2 or 3 CRC. All participants had completed standard treatment regimens within 6 weeks and 1 year before study enrolment; all were above the age of 20 years. Those with histories of cancer, chronic diseases and abnormal liver and kidney function were excluded.

Participant QoL was assessed using the Functional Assessment of Cancer Therapy (FACT)-General (FACT-G), total FACT-cancer-related (FACT-C) and total FACT-fatigue (FACT-F) questionnaires. Serum chemerin, white blood cell count, total cholesterol, triglyceride and fasting insulin levels, among other markers, were measured from blood samples.

The mean serum chemerin level of the participants was 104.69±14.31 ng/mL.Stage 2 and 3 CRC was reported in 49.1 (n=54) and 50.9 (n=56) percent of the participants, respectively. Furthermore, 91.8 (n=101) and 8.2 (n=9) percent were treated with surgery pluschemotherapy and surgery plus chemoradiotherapy, respectively.

Mean FACT-G, FACT-C and FACT-F scores were 80.57±13.68, 100.89±16.53 and 122.40±19.40, respectively. FACT-G scores were significantly negatively correlated with age (p=0.04), fat percentage (p=0.04), triglyceride levels (p=0.02), high-sensitivity C-reactive protein (hsCRP; p=0.02) and serum chemerin levels (p<0.01).

Similarly, FACT-C scores were negatively associated with triglyceride (p=0.02), hsCRP (p=0.02), fat percentage (p=0.04), age (p=0.04) and serum chemerin levels (p<0.01). On the other hand, only triglyceride (p=0.02) and serum chemerin (p<0.01) were significantly negatively associated with FACT-F scores.

Finally, even after adjusting for potential confounders, FACT-G (β, -0.12; p=0.02), FACT-C (β, -0.14; p=0.02) and FACT-F (β, -0.20; p<0.01) were still significantly independently associated with serum chemerin.

Editor's Recommendations
Most Read Articles
one year ago
Cannabinoid hyperemesis syndrome (CHS) should be regarded as an important differential diagnosis in recurrent nausea and vomiting, according to a retrospective cohort study .
Jackey Suen, one year ago
Several biomarker candidates may improve screening and monitoring of treatment response in colorectal cancer (CRC), inflammatory bowel disease (IBD) and hepatocellular carcinoma (HCC), say experts of the Department of Medicine and Therapeutics, Chinese University of Hong Kong (CUHK), at the CUHK’s Advances in Medicine 2015 conference.
one year ago
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.
one year ago
In an exclusive interview with MIMS Doctor, renowned gastroenterologists from Subang Jaya Medical Centre, Dr Tan Soon Seng and Dr Ranjeev C K Prabhakeran,
shared their perspectives and experiences on the use of Fuse® (Full Spectrum Endoscopy) in their clinical practice. Both of them have been practicing gastroenterology
for almost 20 years and have completed more than 1,200 procedures using the Fuse® system.

Fuse® has been available in Malaysia since January 2015. Subang Jaya Medical Centre is the first medical centre in Asia and the ONLY one in Malaysia to use the
Fuse® at the present moment. As cited in The Lancet Oncology,1 March 2014, Fuse® Endoscopy System detected 69% more pre-cancerous polyps than standard forwardviewing colonoscopy.